AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)–Thrombolysis in Myocardial Infarction (TIMI) 57 Trial

BACKGROUND—Lipoprotein(a) [Lp(a)] is an emerging risk factor for cardiovascular disease. Currently, there are few available therapies to lower Lp(a). We sought to evaluate the impact of AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), on Lp(a). METHODS AND...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2013-08, Vol.128 (9), p.962-969
Hauptverfasser:	Desai, Nihar R., Kohli, Payal, Giugliano, Robert P., O’Donoghue, Michelle L., Somaratne, Ransi, Zhou, Jing, Hoffman, Elaine B., Huang, Fannie, Rogers, William J., Wasserman, Scott M., Scott, Robert, Sabatine, Marc S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal - therapeutic use Biological and medical sciences Biomarkers - blood Blood and lymphatic vessels Cardiology. Vascular system Cholesterol, LDL - blood Coronary heart disease Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Disorders of blood lipids. Hyperlipoproteinemia Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Female Heart Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypercholesterolemia - blood Hypercholesterolemia - drug therapy Lipoprotein(a) - blood Logistic Models Male Medical sciences Metabolic diseases Middle Aged Myocardial Infarction - drug therapy Myocarditis. Cardiomyopathies Proprotein Convertase 9 Proprotein Convertases - immunology Risk Factors Serine Endopeptidases - immunology Thrombolytic Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!